MedImmune, Inc. v. Genentech, Inc.
The Court ruled that a drug company did not have to stop paying royalties or break its patent license before asking a federal court to declare the underlying patent invalid or not infringed.
The decision means licensees no longer have to risk being sued for huge damages just to get their day in court, giving companies a safer path to challenge patents they believe are invalid while still meeting their contractual obligations.
“the requirements of [a] case or controversy are met where payment of a claim is demanded as of right and where payment is made, but where the involuntary or coercive nature of the exaction preserves the right to recover the sums paid or to challenge the legality of the claim.”
Explains why paying disputed royalties under protest still leaves a real legal dispute for courts to resolve.
How it got here: A federal trial court dismissed the case for lack of jurisdiction under circuit precedent, and the Federal Circuit affirmed; the Supreme Court agreed to review.
The Case in Depth
What happened
A drug company that made a children's respiratory medicine had licensed patent rights from a biotech company and its co-owner. After a pending patent application turned into an issued patent, the biotech company demanded royalties, threatening to sue for infringement and seek an injunction if the drug company didn't pay. The drug company believed the patent was invalid and not infringed, but paid under protest to avoid losing most of its revenue from the drug, then sued for a declaration that no royalties were owed.
The question before the Court
Does a company that keeps paying royalties under a patent license, rather than breaking the license first, still have the right to go to court and challenge the patent's validity?
The Court's answer
Yes — the Court ruled that a patent licensee does not have to stop paying royalties or breach its license agreement before asking a federal court to decide whether the underlying patent is invalid or not infringed. Continuing to pay disputed royalties under protest, rather than risking a lawsuit for treble damages and an injunction, does not turn a real legal dispute into a hypothetical one.
The Court reasoned that just as someone threatened with government prosecution doesn't have to break the law first to challenge it in court, a licensee threatened with a private infringement suit shouldn't have to risk crippling damages just to get into court. Because the drug company's royalty payments were effectively coerced by the threat of treble damages and losing most of its revenue, a genuine, immediate dispute existed despite the ongoing payments.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Companies that license patented technology can now challenge a patent's validity in court while continuing to pay royalties, instead of having to breach their license and risk crippling damages first. This makes it easier for licensees to contest questionable patents, potentially affecting royalty negotiations and patent litigation strategy across many industries.
What changes now
The case returns to the lower courts, which must now actually decide the merits of the patent-validity and noninfringement claims that were previously dismissed for lack of jurisdiction. The Court left open, for consideration on remand, whether the trial court should still decline to hear the case for discretionary or equitable reasons, as well as any merits-based defenses respondents may raise.
What this does not decide
The Court did not decide whether the license agreement or common-law rules ultimately bar the drug company's claims on the merits, nor whether a non-repudiating licensee is excused from paying royalties while challenging a patent. It also left open whether the trial court should exercise its discretion to dismiss the case anyway.
Concurrences and dissents
Dissent — Justice Thomas
Justice Thomas argued there was no real case or controversy because the drug company faced no actual threat of suit while it remained a licensee in good standing, so its claim was really just a request for an advisory opinion about a future affirmative defense. He rejected treating the company's contract claim as genuine, calling it a repackaged patent-invalidity argument, and objected that the majority improperly extended Steffel v. Thompson's coercion rationale from government threats to private contractual obligations with no limiting principle.
How the Court got there
The legal reasoning, step by step
- The Court framed the question as whether Article III's case-or-controversy requirement, which limits federal courts to real disputes rather than hypothetical ones, is satisfied even though the licensee kept paying royalties instead of breaking the agreement.
- The Court explained that where a party faces a genuine threat of enforcement by the government, it need not expose itself to actual liability or violate the law before suing to challenge the threat, because avoiding the violation is itself a coerced choice that does not erase the real dispute.
- The Court extended this coercion principle to threats from private parties, relying on its earlier decision in Altvater v. Freeman, which held that a licensee's continued royalty payments under protest did not make a patent-validity dispute hypothetical, because the payments were made under the threat of treble damages.
- Applying that principle here, the Court found the drug company's continued royalty payments were similarly coerced by the threat of treble damages, attorney's fees, and an injunction that could have wiped out most of its revenue, so the dispute remained real and immediate.
- The Court rejected the argument that entering the license agreement amounted to a settlement barring any later challenge, finding nothing in the contract's text that stripped the licensee of the right to contest the patent's validity while paying royalties.
- Because the dispute was genuine and not eliminated merely by continued payment, the Court concluded that federal courts had jurisdiction to hear the declaratory-judgment claims.
Doctrinal impact
Cases affected by this decision
Reaffirms Altvater v. Freeman (319 U. S. 359)
The Court relied on Altvater's holding that coerced royalty payments do not defeat jurisdiction over a validity dispute.